title: [Characteristics of 4 specific target antigens in adult acute lymphoblastic leukemia].
abstract: This study was aimed to investigate clinical and prognostic significances of 4 target antigens (CD19, CD20, CD22 and CD33) for antibody-based immunotherapy and to evaluate the applications of these antibody-based target therapy to adult acute lymphoblastic leukemia (ALL). The immunophenotype of 220 adult patients with ALL were analyzed by four-color flow Cytometry, and cytogenetic and molecular parameters were detected by conventional cytogenetics, fluorescence in situ hybridization, real-time quantitative PCR, nested PCR and DNA sequencing. The results showed that CD19 positive (CD19(+)) cases were more in female (46.4% vs. 23.4%, P = 0.006), elderly patients aged > 60 years (14.4% vs. 2.1%, P = 0.022), CD33(+) co-expression cases (47.8% vs. 12.0%, P = 0.001) and genetic high-risk group (55.8% vs. 20.8%, P = 0.002) compared with CD19 negative (CD19(-)) cases; CD20(+) cases had lower co-expression of CD13 than CD20(-) cases (31.6% vs.67.1%, P = 0.000) and no significant prognostic indications for CD20(+) was observed; CD22(+) cases had higher relapse rate at 12-month than CD22(-) cases (93.9% vs.57.1%, P = 0.041) in B-ALL patients; CD33(+) cases had higher incidence of Ph(+) than CD33(-) cases (43.5% vs.19.4%, P = 0.007) and significantly correlated with Ph(+) (r = 0.261, P = 0.006). It is concluded that elucidation of the characteristics of the target antigens (CD19, CD20, CD22, CD33) used for antibody-based immunotherapy will help hematologists making the correct decision whether and when to use these antibody-based target therapies.
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province, China.
authors.forename: Zhong-Kun
authors.initials: ZK
authors.lastname: Lin
authors.forename: Run
authors.initials: R
authors.lastname: Zhang
authors.forename: Zheng
authors.initials: Z
authors.lastname: Ge
authors.forename: Juan
authors.initials: J
authors.lastname: Liu
authors.forename: Yu-Jie
authors.initials: YJ
authors.lastname: Wu
authors.forename: Xing
authors.initials: X
authors.lastname: Guo
authors.forename: Chun
authors.initials: C
authors.lastname: Qiao
authors.forename: Hai-Rong
authors.initials: HR
authors.lastname: Qiu
authors.forename: Jian-Yong
authors.initials: JY
authors.lastname: Li
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018941:Antigens, CD19 / Q000276:immunology*; D018951:Antigens, CD20 / Q000276:immunology*; D002648:Child; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D008297:Male; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics / Q000276:immunology*; D051918:Sialic Acid Binding Ig-like Lectin 2 / Q000276:immunology*; D063268:Sialic Acid Binding Ig-like Lectin 3 / Q000276:immunology*; D055815:Young Adult
chemical_list: D018941:Antigens, CD19; D018951:Antigens, CD20; D051918:Sialic Acid Binding Ig-like Lectin 2; D063268:Sialic Acid Binding Ig-like Lectin 3